March 21, 2018New England Journal of Medicine4,718 citationsOpen Access
View Full PaperNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).